These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33035424)

  • 1. Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.
    Wilson MW; Shu L; Hinkovska-Galcheva V; Jin Y; Rajeswaran W; Abe A; Zhao T; Luo R; Wang L; Wen B; Liou B; Fannin V; Sun D; Sun Y; Shayman JA; Larsen SD
    ACS Chem Neurosci; 2020 Oct; 11(20):3464-3473. PubMed ID: 33035424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial.
    Schiffmann R; Cox TM; Dedieu JF; Gaemers SJM; Hennermann JB; Ida H; Mengel E; Minini P; Mistry P; Musholt PB; Scott D; Sharma J; Peterschmitt MJ
    Brain; 2023 Feb; 146(2):461-474. PubMed ID: 36256599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
    Bennett LL; Turcotte K
    Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.
    Balwani M; Burrow TA; Charrow J; Goker-Alpan O; Kaplan P; Kishnani PS; Mistry P; Ruskin J; Weinreb N
    Mol Genet Metab; 2016 Feb; 117(2):95-103. PubMed ID: 26387627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.
    Cox TM
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1169-81. PubMed ID: 20872320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy.
    Pavlova EV; Archer J; Wang S; Dekker N; Aerts JM; Karlsson S; Cox TM
    J Pathol; 2015 Jan; 235(1):113-24. PubMed ID: 25256118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eliglustat: first global approval.
    Poole RM
    Drugs; 2014 Oct; 74(15):1829-36. PubMed ID: 25239269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
    Lukina E; Watman N; Arreguin EA; Banikazemi M; Dragosky M; Iastrebner M; Rosenbaum H; Phillips M; Pastores GM; Rosenthal DI; Kaper M; Singh T; Puga AC; Bonate PL; Peterschmitt MJ
    Blood; 2010 Aug; 116(6):893-9. PubMed ID: 20439622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of Glucosylceramide Synthase.
    Shayman JA; Hinkovska-Galcheva V; Shu L
    Methods Mol Biol; 2023; 2613():271-288. PubMed ID: 36587085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
    Belmatoug N; Di Rocco M; Fraga C; Giraldo P; Hughes D; Lukina E; Maison-Blanche P; Merkel M; Niederau C; PlÓ§ckinger U; Richter J; Stulnig TM; Vom Dahl S; Cox TM
    Eur J Intern Med; 2017 Jan; 37():25-32. PubMed ID: 27522145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
    Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris Feldman H; Ghosn M; Mehta A; Packman S; Lau H; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Foster MC; Gaemers SJM; Peterschmitt MJ
    Am J Hematol; 2021 Sep; 96(9):1156-1165. PubMed ID: 34161616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity?
    Shayman JA
    Trans Am Clin Climatol Assoc; 2013; 124():46-60. PubMed ID: 23874009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.
    Marshall J; Sun Y; Bangari DS; Budman E; Park H; Nietupski JB; Allaire A; Cromwell MA; Wang B; Grabowski GA; Leonard JP; Cheng SH
    Mol Ther; 2016 Jun; 24(6):1019-1029. PubMed ID: 26948439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
    McEachern KA; Fung J; Komarnitsky S; Siegel CS; Chuang WL; Hutto E; Shayman JA; Grabowski GA; Aerts JM; Cheng SH; Copeland DP; Marshall J
    Mol Genet Metab; 2007 Jul; 91(3):259-67. PubMed ID: 17509920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
    Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
    Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease.
    Blumenreich S; Yaacobi C; Vardi A; Barav OB; Vitner EB; Park H; Wang B; Cheng SH; Sardi SP; Futerman AH
    J Neurochem; 2021 Mar; 156(5):692-701. PubMed ID: 32743826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
    Lukina E; Watman N; Dragosky M; Lau H; Avila Arreguin E; Rosenbaum H; Zimran A; Foster MC; Gaemers SJM; Peterschmitt MJ
    Am J Hematol; 2019 Jan; 94(1):29-38. PubMed ID: 30264864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease.
    Cabrera-Salazar MA; Deriso M; Bercury SD; Li L; Lydon JT; Weber W; Pande N; Cromwell MA; Copeland D; Leonard J; Cheng SH; Scheule RK
    PLoS One; 2012; 7(8):e43310. PubMed ID: 22912851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
    Mistry PK; Lukina E; Ben Turkia H; Amato D; Baris H; Dasouki M; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Shankar S; Solano MH; Ross L; Angell J; Peterschmitt MJ
    JAMA; 2015 Feb; 313(7):695-706. PubMed ID: 25688781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers.
    Peterschmitt MJ; Crawford NPS; Gaemers SJM; Ji AJ; Sharma J; Pham TT
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):86-98. PubMed ID: 32851809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.